publication venue for
- Estrogen Receptor β Is a Novel Target in Acute Myeloid Leukemia. 16:2618-2626. 2017
- ABT-898 Induces Tumor Regression and Prolongs Survival in a Mouse Model of Epithelial Ovarian Cancer. 10:1876-1885. 2011
- Pancratistatin Selectively Targets Cancer Cell Mitochondria and Reduces Growth of Human Colon Tumor Xenografts. 10:57-68. 2011
- ABT-510 induces tumor cell apoptosis and inhibits ovarian tumor growth in an orthotopic, syngeneic model of epithelial ovarian cancer. 8:64-74. 2009
- Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect. 6:570-577. 2007
- Effects of the chemotherapeutic agent doxorubicin on the protein C anticoagulant pathway. 5:3303-3311. 2006
- Role of the transcription factor Ets-1 in cisplatin resistance.. 3:823-832. 2004
- Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.. 1:545-552. 2002
- Abstract A185: Phase I clinical, pharmacokinetic, and pharmacodynamic study of SB939, an oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumors 2009
- Abstract B54: A phase 1 study to assess the safety, tolerability and pharmacokinetics of the ErbB‐family inhibitor ARRY‐334543 in patients with advanced solid tumors 2009
- A phase 1 study of selective cyclin dependent kinase inhibitor P276-00 in patients with advanced refractory neoplasms 2007
- AZD2171 (Cediranib) is active in first line metastatic renal cell carcinoma (RCC): Interim results of a phase II trial. A trial of the PMH Phase II Consortium 2007
- Fluororescence in situ hybridization (FISH) gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors (MSGT) treated with lapatinib 2007
- Phase I/II study of CTCE-9908, a novel anticancer agent that inhibits CXCR4, in patients with advanced solid cancers 2007